Cargando…

Cardiovascular Morbidity in Monoclonal Gammopathy of Undetermined Significance: A Danish Nationwide Study

BACKGROUND: Monoclonal gammopathy of undetermined significance (MGUS) is associated with renal dysfunction, inflammation, and increased cardiovascular mortality, but the cardiovascular risks are not fully understood. OBJECTIVES: The authors explored the association of MGUS with a spectrum of cardiov...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwartz, Brian, Schou, Morten, Ruberg, Frederick L., Rucker, Dane, Choi, Jihoon, Siddiqi, Omar, Monahan, Kevin, Køber, Lars, Gislason, Gunnar, Torp-Pedersen, Christian, Andersson, Charlotte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537076/
https://www.ncbi.nlm.nih.gov/pubmed/36213365
http://dx.doi.org/10.1016/j.jaccao.2022.05.009
_version_ 1784803118410629120
author Schwartz, Brian
Schou, Morten
Ruberg, Frederick L.
Rucker, Dane
Choi, Jihoon
Siddiqi, Omar
Monahan, Kevin
Køber, Lars
Gislason, Gunnar
Torp-Pedersen, Christian
Andersson, Charlotte
author_facet Schwartz, Brian
Schou, Morten
Ruberg, Frederick L.
Rucker, Dane
Choi, Jihoon
Siddiqi, Omar
Monahan, Kevin
Køber, Lars
Gislason, Gunnar
Torp-Pedersen, Christian
Andersson, Charlotte
author_sort Schwartz, Brian
collection PubMed
description BACKGROUND: Monoclonal gammopathy of undetermined significance (MGUS) is associated with renal dysfunction, inflammation, and increased cardiovascular mortality, but the cardiovascular risks are not fully understood. OBJECTIVES: The authors explored the association of MGUS with a spectrum of cardiovascular diseases using the Danish nationwide databases. METHODS: Between 1995 and 2018, patients 18 years and older with MGUS were age- and sex-matched (1:10) with control patients and followed prospectively until December 31, 2018, for the occurrence of cardiovascular diseases. Patients diagnosed with multiple myeloma, lymphoma, or amyloidosis were excluded. Multivariable adjusted hazard ratios (HRs) for cardiovascular outcomes were estimated using Cox proportional hazard regression. RESULTS: Patients with MGUS (n = 8,189; mean age 69.8 ± 11.7 years; 51.2% male) had higher prevalence of cardiovascular risk factors at baseline, including hypertension (48.0% vs 38.5%) and type 2 diabetes (13.0% vs 9.3%), compared with control patients. Outcomes included an increased risk of heart failure (HR: 1.55; 95% CI: 1.41-1.69), acute myocardial infarction (HR: 1.22; 95% CI: 1.06-1.40), ischemic stroke (HR: 1.16; 95% CI: 1.03-1.30), atrial fibrillation (HR: 1.32; 95% CI: 1.23-1.42), aortic aneurysm (HR: 1.55; 95% CI: 1.28-1.89), aortic stenosis (HR: 1.60; 95% CI: 1.41-1.82), aortic regurgitation (HR: 1.67; 95% CI: 1.34-2.07), heart block (HR: 1.32; 95% CI: 1.08-1.61), peripheral artery disease (HR: 1.69; 95% CI: 1.47-1.95), cor pulmonale (HR: 2.06; 95% CI: 1.55-2.73), and venous thromboembolism (HR: 1.43; 95% CI: 1.24-1.65). A sensitivity analysis including only patients without certain comorbidities (type 2 diabetes, hypertension, acute myocardial infarction, and chronic kidney disease) yielded similar results. CONCLUSIONS: MGUS is associated with a broad spectrum of cardiovascular diseases, with greater relative risks observed for diseases previously associated with infiltrative and inflammatory disorders. Further studies are warranted to explore the underlying mechanisms.
format Online
Article
Text
id pubmed-9537076
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-95370762022-10-08 Cardiovascular Morbidity in Monoclonal Gammopathy of Undetermined Significance: A Danish Nationwide Study Schwartz, Brian Schou, Morten Ruberg, Frederick L. Rucker, Dane Choi, Jihoon Siddiqi, Omar Monahan, Kevin Køber, Lars Gislason, Gunnar Torp-Pedersen, Christian Andersson, Charlotte JACC CardioOncol Original Research BACKGROUND: Monoclonal gammopathy of undetermined significance (MGUS) is associated with renal dysfunction, inflammation, and increased cardiovascular mortality, but the cardiovascular risks are not fully understood. OBJECTIVES: The authors explored the association of MGUS with a spectrum of cardiovascular diseases using the Danish nationwide databases. METHODS: Between 1995 and 2018, patients 18 years and older with MGUS were age- and sex-matched (1:10) with control patients and followed prospectively until December 31, 2018, for the occurrence of cardiovascular diseases. Patients diagnosed with multiple myeloma, lymphoma, or amyloidosis were excluded. Multivariable adjusted hazard ratios (HRs) for cardiovascular outcomes were estimated using Cox proportional hazard regression. RESULTS: Patients with MGUS (n = 8,189; mean age 69.8 ± 11.7 years; 51.2% male) had higher prevalence of cardiovascular risk factors at baseline, including hypertension (48.0% vs 38.5%) and type 2 diabetes (13.0% vs 9.3%), compared with control patients. Outcomes included an increased risk of heart failure (HR: 1.55; 95% CI: 1.41-1.69), acute myocardial infarction (HR: 1.22; 95% CI: 1.06-1.40), ischemic stroke (HR: 1.16; 95% CI: 1.03-1.30), atrial fibrillation (HR: 1.32; 95% CI: 1.23-1.42), aortic aneurysm (HR: 1.55; 95% CI: 1.28-1.89), aortic stenosis (HR: 1.60; 95% CI: 1.41-1.82), aortic regurgitation (HR: 1.67; 95% CI: 1.34-2.07), heart block (HR: 1.32; 95% CI: 1.08-1.61), peripheral artery disease (HR: 1.69; 95% CI: 1.47-1.95), cor pulmonale (HR: 2.06; 95% CI: 1.55-2.73), and venous thromboembolism (HR: 1.43; 95% CI: 1.24-1.65). A sensitivity analysis including only patients without certain comorbidities (type 2 diabetes, hypertension, acute myocardial infarction, and chronic kidney disease) yielded similar results. CONCLUSIONS: MGUS is associated with a broad spectrum of cardiovascular diseases, with greater relative risks observed for diseases previously associated with infiltrative and inflammatory disorders. Further studies are warranted to explore the underlying mechanisms. Elsevier 2022-07-19 /pmc/articles/PMC9537076/ /pubmed/36213365 http://dx.doi.org/10.1016/j.jaccao.2022.05.009 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research
Schwartz, Brian
Schou, Morten
Ruberg, Frederick L.
Rucker, Dane
Choi, Jihoon
Siddiqi, Omar
Monahan, Kevin
Køber, Lars
Gislason, Gunnar
Torp-Pedersen, Christian
Andersson, Charlotte
Cardiovascular Morbidity in Monoclonal Gammopathy of Undetermined Significance: A Danish Nationwide Study
title Cardiovascular Morbidity in Monoclonal Gammopathy of Undetermined Significance: A Danish Nationwide Study
title_full Cardiovascular Morbidity in Monoclonal Gammopathy of Undetermined Significance: A Danish Nationwide Study
title_fullStr Cardiovascular Morbidity in Monoclonal Gammopathy of Undetermined Significance: A Danish Nationwide Study
title_full_unstemmed Cardiovascular Morbidity in Monoclonal Gammopathy of Undetermined Significance: A Danish Nationwide Study
title_short Cardiovascular Morbidity in Monoclonal Gammopathy of Undetermined Significance: A Danish Nationwide Study
title_sort cardiovascular morbidity in monoclonal gammopathy of undetermined significance: a danish nationwide study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537076/
https://www.ncbi.nlm.nih.gov/pubmed/36213365
http://dx.doi.org/10.1016/j.jaccao.2022.05.009
work_keys_str_mv AT schwartzbrian cardiovascularmorbidityinmonoclonalgammopathyofundeterminedsignificanceadanishnationwidestudy
AT schoumorten cardiovascularmorbidityinmonoclonalgammopathyofundeterminedsignificanceadanishnationwidestudy
AT rubergfrederickl cardiovascularmorbidityinmonoclonalgammopathyofundeterminedsignificanceadanishnationwidestudy
AT ruckerdane cardiovascularmorbidityinmonoclonalgammopathyofundeterminedsignificanceadanishnationwidestudy
AT choijihoon cardiovascularmorbidityinmonoclonalgammopathyofundeterminedsignificanceadanishnationwidestudy
AT siddiqiomar cardiovascularmorbidityinmonoclonalgammopathyofundeterminedsignificanceadanishnationwidestudy
AT monahankevin cardiovascularmorbidityinmonoclonalgammopathyofundeterminedsignificanceadanishnationwidestudy
AT køberlars cardiovascularmorbidityinmonoclonalgammopathyofundeterminedsignificanceadanishnationwidestudy
AT gislasongunnar cardiovascularmorbidityinmonoclonalgammopathyofundeterminedsignificanceadanishnationwidestudy
AT torppedersenchristian cardiovascularmorbidityinmonoclonalgammopathyofundeterminedsignificanceadanishnationwidestudy
AT anderssoncharlotte cardiovascularmorbidityinmonoclonalgammopathyofundeterminedsignificanceadanishnationwidestudy